1
|
Lin Z, Shen Y, Li Y, Lu C, Zhu Y, He R, Cao Z, Yin Z, Gao H, Guo B, Ma X, Cao M, Luo M. Novel compound heterozygous variants in ARL13B lead to Joubert syndrome. J Cell Physiol 2024; 239:e31189. [PMID: 38219074 DOI: 10.1002/jcp.31189] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/04/2023] [Revised: 12/07/2023] [Accepted: 12/22/2023] [Indexed: 01/15/2024]
Abstract
Joubert syndrome (JBTS) is a systematic developmental disorder mainly characterized by a pathognomonic mid-hindbrain malformation. All known JBTS-associated genes encode proteins involved in the function of antenna-like cellular organelle, primary cilium, which plays essential roles in cellular signal transduction and development. Here, we identified four unreported variants in ARL13B in two patients with the classical features of JBTS. ARL13B is a member of the Ras GTPase family and functions in ciliogenesis and cilia-related signaling. The two missense variants in ARL13B harbored the substitutions of amino acids at evolutionarily conserved positions. Using model cell lines, we found that the accumulations of the missense variants in cilia were impaired and the variants showed attenuated functions in ciliogenesis or the trafficking of INPP5E. Overall, these findings expanded the ARL13B pathogenetic variant spectrum of JBTS.
Collapse
Affiliation(s)
- Zaisheng Lin
- International Peace Maternity and Child Health Hospital, Key Laboratory of Cell Differentiation and Apoptosis of Chinese Ministry of Education, Department of Pathophysiology, Shanghai Jiao Tong University School of Medicine, Shanghai, China
| | - Yue Shen
- National Human Genetic Resources Center, National Research Institute for Family Planning, Beijing, China
| | - Yan Li
- International Peace Maternity and Child Health Hospital, Key Laboratory of Cell Differentiation and Apoptosis of Chinese Ministry of Education, Department of Pathophysiology, Shanghai Jiao Tong University School of Medicine, Shanghai, China
| | - Chao Lu
- National Human Genetic Resources Center, National Research Institute for Family Planning, Beijing, China
| | - Ying Zhu
- International Peace Maternity and Child Health Hospital, Key Laboratory of Cell Differentiation and Apoptosis of Chinese Ministry of Education, Department of Pathophysiology, Shanghai Jiao Tong University School of Medicine, Shanghai, China
| | - Ruida He
- International Peace Maternity and Child Health Hospital, Key Laboratory of Cell Differentiation and Apoptosis of Chinese Ministry of Education, Department of Pathophysiology, Shanghai Jiao Tong University School of Medicine, Shanghai, China
| | - Zongfu Cao
- National Human Genetic Resources Center, National Research Institute for Family Planning, Beijing, China
| | - Zhe Yin
- National Human Genetic Resources Center, National Research Institute for Family Planning, Beijing, China
| | - Huafang Gao
- National Human Genetic Resources Center, National Research Institute for Family Planning, Beijing, China
| | - Bin Guo
- International Peace Maternity and Child Health Hospital, Key Laboratory of Cell Differentiation and Apoptosis of Chinese Ministry of Education, Department of Pathophysiology, Shanghai Jiao Tong University School of Medicine, Shanghai, China
| | - Xu Ma
- National Human Genetic Resources Center, National Research Institute for Family Planning, Beijing, China
| | - Muqing Cao
- International Peace Maternity and Child Health Hospital, Key Laboratory of Cell Differentiation and Apoptosis of Chinese Ministry of Education, Department of Pathophysiology, Shanghai Jiao Tong University School of Medicine, Shanghai, China
| | - Minna Luo
- National Human Genetic Resources Center, National Research Institute for Family Planning, Beijing, China
| |
Collapse
|
2
|
Sun TC, Guo YM, Li DM, Wen YJ, Jiao ZX, Li J, Wang HP, Jia YJ, Zhou SJ. Plasma-derived from human umbilical cord blood restores ovarian function and improves serum reproductive hormones levels in mice with premature ovarian insufficiency (POI) through cytokines and growth factors. Mol Reprod Dev 2024; 91:e23731. [PMID: 38404010 DOI: 10.1002/mrd.23731] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/05/2023] [Revised: 12/01/2023] [Accepted: 01/02/2024] [Indexed: 02/27/2024]
Abstract
Premature ovarian insufficiency (POI) patients experience a decline in ovarian function and a reduction in serum reproductive hormones, leading to a significant impact on the outcomes of assisted reproductive technology. Despite the absence of an effective clinical treatment to restore fertility in POI patients, recent research has indicated that cord blood plasma (CBP) derived from human umbilical cord blood (hUCB) may offer therapeutic benefits for various degenerative diseases. The primary aim of this study is to explore approaches for enhancing ovarian function and serum reproductive hormones through the administration of CBP in a murine model. Initially, hUCB was utilized to obtain CBP (CBP), which was subsequently analyzed for cytokine and growth factor profiles in comparison to adult blood plasma (ABP) by use of flow cytometry. Subsequently, POI mouse models were established through the induction of 4-vinylcyclohexene diepoxide, followed by the injection of CBP into the tail. At 7, 14, and 21 days posttreatment, mouse ovaries and blood were collected, and their estrus cycle, body weight, and ovarian weights were evaluated using precise electronic balance. Finally, ovarian morphology and follicle number were assessed through HE staining, while serum levels of anti-Müllerian hormone (AMH), estradiol (E2) and follicle-stimulating hormone (FSH) were determined by ELISA. Our study revealed that individuals with CBP exhibited significantly lower concentrations of proinflammatory cytokines, including IL-β (p < 0.01) and IL-2 (p < 0.05), while displaying elevated levels of anti-inflammatory cytokines and chemokines, such as IL-2, IL-4, IL-6, IL-8, IL-12P70, IL-17A, IP-10, interferon-γ, and tumor necrosis factor-α (p < 0.01). Furthermore, CBP demonstrated remarkably higher levels of growth factors, including transforming growth factor-β1, vascular endothelial growth factor, and insulin-like growth factor-1 (p < 0.01) than ABP. Notably, our investigation also revealed that CBP restored the content of serum reproductive hormones, such as AMH, E2, and FSH (p < 0.05), and increased the number of primordial and primary follicles (p < 0.01) and decreased the number of luteal and atretic follicles (p < 0.01) in vivo. Our findings suggested that CBP-secreted cytokines and growth factors could be restored POI ovarian function, enhanced serum reproductive hormones and rescued follicular development in vivo. These findings further support the potential of CBP as a promising strategy in clinical applications for POI related infertility.
Collapse
Affiliation(s)
- Tie Cheng Sun
- Department of Obstetrics and Gynecology, Reproductive Medical Center, Peking University International Hospital, Beijing, China
- HLA Laboratory, Beijing Red Cross Blood Center, Beijing, China
| | - Yi Ming Guo
- Graduate School of Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China
- NHC Key Laboratory of Reproductive Health Engineering Technology Research (NRIFP), National Research Institute for Family Planning, Beijing, China
| | - Dong Mei Li
- Department of Obstetrics and Gynecology, Reproductive Medical Center, Peking University International Hospital, Beijing, China
| | - Yu Jie Wen
- Department of Obstetrics and Gynecology, Reproductive Medical Center, Peking University International Hospital, Beijing, China
| | - Zhu Xue Jiao
- Department of Obstetrics and Gynecology, Reproductive Medical Center, Peking University International Hospital, Beijing, China
| | - Ju Li
- Department of Obstetrics and Gynecology, Reproductive Medical Center, Peking University International Hospital, Beijing, China
| | - Hui Ping Wang
- Graduate School of Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China
- NHC Key Laboratory of Reproductive Health Engineering Technology Research (NRIFP), National Research Institute for Family Planning, Beijing, China
| | - Yan Jun Jia
- Department of Obstetrics and Gynecology, Reproductive Medical Center, Peking University International Hospital, Beijing, China
| | - Shan Jie Zhou
- Department of Obstetrics and Gynecology, Reproductive Medical Center, Peking University International Hospital, Beijing, China
| |
Collapse
|